{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:12:00Z","timestamp":1761901920224,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103285","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:44:03Z","timestamp":1632779043000},"page":"103285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy"],"prefix":"10.1016","volume":"56","author":[{"given":"Elizabeth C.S.","family":"Swart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Mager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rock A.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rochelle","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiraat","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester B.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2021.103285_bib0001","first-page":"e1029","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data [published correction appears in Neurology. 2019 Oct 8;93(15):688]","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103285_bib0002","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14656566.2019.1615880","article-title":"Pharmacoeconomics of synthetic therapies for multiple sclerosis","volume":"20","author":"D'Amico","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.msard.2021.103285_bib0003","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","article-title":"Economics and cost-effectiveness of multiple sclerosis therapies in the USA","volume":"14","author":"Hartung","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2021.103285_bib0004","doi-asserted-by":"crossref","first-page":"k4674","DOI":"10.1136\/bmj.k4674","article-title":"Brownlee W J. Disease-modifying therapies for multiple sclerosis","volume":"363","author":"De Angelis","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103285_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2021.103285_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2021.103285_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment","author":"Otero-Romero","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2021.103285_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult. Scler"},{"issue":"8","key":"10.1016\/j.msard.2021.103285_bib0009","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:15Z","timestamp":1761901215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":9,"alternative-id":["S2211034821005526"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103285","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103285"}}